Journal
VETERINARY JOURNAL
Volume 194, Issue 2, Pages 151-157Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.tvjl.2012.06.031
Keywords
Porcine circovirus type 2; Postweaning multisystemic wasting syndrome; Porcine circovirus-associated disease; Vaccine
Categories
Funding
- Technology Development Programme for Agriculture and Forestry, Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea
- Research Institute for Veterinary Science (RIVS) from the College of Veterinary Medicine
- Brain Korea 21 Programme for Veterinary Science
- Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry & Fisheries (iPET), Republic of Korea [IPET610004-3] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Porcine circovirus type 2 (PCV2) is the one of the most economically important pathogens of pigs. After postweaning multisystemic wasting syndrome (PMWS) was first identified and reported in western Canada in 1991, it took 13 years for the first commercial PCV2 vaccine to be used under special licence in France and Germany in 2004. Along with PMWS, PCV2 is also associated with a number of diseases and syndromes, collectively referred to as porcine circovirus-associated disease (PCVAD). Currently, five commercial vaccines are available on the international market. Commercial PCV2 vaccines were initially developed to control PMWS, but they are now also used against other PCVAD. This review focuses on (1) the types of commercial vaccines; (2) the criteria of vaccine efficacy; (3) the clinical, virological, immunological and pathological efficacy of the vaccines; and (4) the use of PCV2 vaccines against different clinical manifestations of PCVAD. (c) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
